The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
about
IFI16 is an innate immune sensor for intracellular DNAInnate immune recognition of an AT-rich stem-loop DNA motif in the Plasmodium falciparum genomeA host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMPSTING: infection, inflammation and cancerDNA vaccines: a simple DNA sensing matter?Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvantsCell Type-Specific Recognition of Human Metapneumoviruses (HMPVs) by Retinoic Acid-Inducible Gene I (RIG-I) and TLR7 and Viral Interference of RIG-I Ligand Recognition by HMPV-B1 PhosphoproteinSpecies-specific detection of the antiviral small-molecule compound CMA by STINGInternational Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and diseaseInterferons and viruses: an evolutionary arms race of molecular interactionsRat and human STINGs profile similarly towards anticancer/antiviral compoundsInteraction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironmentVascular disrupting agent drug classes differ in effects on the cytoskeletonHigh throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discoveryThe AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA virusesCombining vasculature disrupting agent and Toll-like receptor 7/8 agonist for cancer therapy.The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo.Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists.Identification of host cytosolic sensors and bacterial factors regulating the type I interferon response to Legionella pneumophilaNOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis.Type I Interferon Induction by Neisseria gonorrhoeae: Dual Requirement of Cyclic GMP-AMP Synthase and Toll-like Receptor 4.Cytosolic-DNA-mediated, STING-dependent proinflammatory gene induction necessitates canonical NF-κB activation through TBK1Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).TRIL is involved in cytokine production in the brain following Escherichia coli infection.Host-cell sensors for Plasmodium activate innate immunity against liver-stage infectionThe SKIV2L RNA exosome limits activation of the RIG-I-like receptorsLabeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action.5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potentialMouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acidCD14 is a coreceptor of Toll-like receptors 7 and 9.TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria.TRAM is required for TLR2 endosomal signaling to type I IFN inductionThe chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity.Transcriptional analysis of murine macrophages infected with different Toxoplasma strains identifies novel regulation of host signaling pathwaysViral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections.Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulationPharmacologic activation of the innate immune system to prevent respiratory viral infections.Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance
P2860
Q24301720-32C67ACC-7DAF-4FC8-A5FA-83EE5779E6FFQ24611264-E9186D96-711D-4410-B97F-8A057F1B6956Q24642631-6EF227B7-97DB-4E17-9CCE-577EB4F40518Q26776009-EF23408E-F940-429B-B6B9-D362010F7874Q26859016-FC4C358F-4499-40BF-AF7F-BAAF58DD34DCQ27025822-48998021-854F-4402-A6B7-4C7E57A5C586Q27491027-184EE6F9-6700-40C3-B44F-D6CDBB759763Q27677466-F97A6AFC-6EEA-4DF5-B783-C39209219F47Q28081406-37332E5E-67CB-46CA-B040-11358877746DQ28083788-2C8AFF90-8A1F-4684-8D6C-144B37C5B2C2Q28118888-E8C281F7-2D72-46D0-B13F-84467D7752EFQ28389479-C3FB2BF2-D313-47C5-9306-4483BFA5E07AQ28481498-CA294549-1B6E-43D1-A68C-DC4EAD90C863Q28483402-7FBBCC0B-DB2C-4754-AAAD-D6E7F6BB48F3Q29614469-BB6DCC24-31DB-412C-A5D7-197418CA6FBAQ30358185-9A93DCD7-5071-4F3E-BF12-7C536AC7F834Q30396361-B2773185-4451-413D-A941-471E90FFEE1CQ30418533-1A4F8CFC-1D97-481C-96E0-7614F8AD8CA5Q30912277-EF2F1617-98E6-4704-ADF4-04203BD5AEBDQ33478396-A1E047C2-BDC1-483C-84B4-06A9DA9C8B9DQ33592743-D25AE3A2-95F9-4AC6-910D-CA698588A153Q33602916-0C986254-2A01-4CE9-92A8-59D3E6B9023AQ33796126-221F4FDF-2EC0-4E0D-A1E7-83F669A6CF88Q33889490-450A8589-A7D2-47CA-A316-6FC929D9F804Q33896690-9A5E1435-F617-4F04-9C6C-66BFA251FFF7Q34071054-A500201B-1B53-40EE-A0B0-9E9F46EAD6A2Q34105372-81B6814E-090E-42D0-AE51-0FD60B4B74D8Q34303159-FF89B7DD-48CA-429C-8FC1-D268C08F490EQ34339243-B0227832-8F1D-4088-AE09-BD800A7DF20BQ34340654-B3D16720-99F8-4FDC-B79C-D9236BF5A31BQ34640637-8AB6700B-8FD5-4CF3-9DFD-DFA45E5E8DC4Q34646268-F3DF80C0-836C-4C62-B1C6-72E1DA327C10Q34653072-90E1898D-8E3A-48D8-9D5D-2F8CFDD92AE0Q34796825-C01F2E42-1E19-45E6-BD46-9654372D52B7Q35075096-955D435C-169D-4587-80F9-EAFA56A0FEBDQ35076123-0B9E6955-B010-423C-A91B-1CBF2B0A7415Q35317995-7BDC2A48-DDEF-407E-B21B-CF802E8AF549Q35692082-5F4AABDF-DDBE-442C-8586-1619E5955BA3Q35832390-438AE2B5-8E42-4DDD-ABCB-C6D9DC644E24Q35845957-A17B9B36-578F-49FA-A56D-4DAD3593B677
P2860
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@ast
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@en
type
label
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@ast
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@en
prefLabel
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@ast
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@en
P2093
P2860
P356
P1476
The chemotherapeutic agent DMX ...... the TBK1-IRF-3 signaling axis.
@en
P2093
David van Echo
Himanshu Kumar
Hiroki Kato
Howard A Young
Katherine A Fitzgerald
Lai-Ming Ching
Nadege Goutagny
Pin-Yu Perera
Stefanie N Vogel
P2860
P304
P356
10.1084/JEM.20061845
P407
P50
P577
2007-06-11T00:00:00Z